ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2114

Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases

Daisuke Kobayashi1, Sayuri Takamura 2, Yoko Wada 3, Takeshi Kuroda 4 and Ichiei Narita 1, 1Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, 2Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, 3Niigata Rinko Hospital, Niigata, Niigata, Japan, 4Health administration office, Niigata University, Niigata, Niigata, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, corticosteroids, opportunistic infections, risk assessment and immunosuppressants

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Infection-Related Rheumatic Disease Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections. It is therefore important to investigate the risk of opportunistic infections to ensure appropriate management of patients with autoimmune disease. Cytomegalovirus (CMV) infection is one of the most common opportunistic infections. Since 2011 we have been performing routine weekly evaluation of CMV pp65 antigen for such patients. Here we investigated the predictive risk factors for CMV infection under remission-induction therapy in patients with autoimmune disease.

Methods: We enrolled 96 patients (male 34, female 62) with autoimmune disease who received remission-induction therapy with prednisolone at over 0.5 mg/kg/day in Niigata University Hospital between January 2017 and December 2018. We retrospectively analyzed their clinical features and laboratory data at the baseline, the treatment regimens used, and the results of CMVpp65 antigen analysis. The presence of more than 5 CMVpp65 antigen-positive cells/2 slides was defined as a positive result. We conducted univariate and multivariate analyses to identify risk factors for CMV positivity.

Results: The enrolled patients included 26 systemic lupus erythematosus (SLE), 18 anti-nucleolar cytoplasmic antibody-associated vasculitis (AAV), 8 interstitial pneumonia with anti-aminoacyl tRNA synthetase antibody, 6 mixed connective tissue disease (MCTD), 6 rheumatoid arthritis, 5 clinically amyopathic dermatomyositis (CADM), 5 adult-onset Still’s disease (AOSD), 5 Takayasu’s aortitis, and 17 other conditions. Methylprednisolone pulse therapy, intravenous cyclophosphamide, oral calcineurin inhibitor, methotrexate, azathioprine, and mycophenolate mofetil were applied in 36 (37.5%), 17 (17.7%), 7 (7.29%), 4 (4.17%), 4 (4.17%), and 3 (3.13%) patients, respectively. The median follow-up duration was 62.5 days, and 21 patients became CMV antigenemia-positive (SLE 9, AOSD 4, AAV 2, CADM 2, MCTD 2, and others 2). Univariate analysis showed that the positivity was associated with a low total lymphocyte count (TLC) (710/μl vs 1330/μl; p< 0.001), a low serum albumin level (2.70 g/dl vs 3.50 g/dl; p< 0.001), a high HbA1c level (6.4% vs 5.9%; p< 0.001), and a high initial prednisolone dosage (0.97 mg/kg/day vs 0.86 mg/kg/day; p< 0.001). Fifteen of the 21 patients in the positive group received steroid pulse therapy (p< 0.001). The Cox hazard regression model indicated that a higher age by decade (OR; 1.46 [95%CI 1.06- 2.00]), a lower TLC per 100/mL (OR; 0.827 [95%CI 0.731-0.935]), a higher HbA1c level per 1% (OR; 2.37 [1.25-4.53]), and mPSL pulse therapy (OR; 3.92 [1.33-11.5]) were independent risk factors for CMV positivity.

Conclusion: Lower TLC, lower serum albumin, higher HbA1c, and receiving steroid pulse therapy were risk factors for CMV pp65 antigen positivity. Careful monitoring is therefore necessary for such patients.


Disclosure: D. Kobayashi, None; S. Takamura, None; Y. Wada, None; T. Kuroda, None; I. Narita, None.

To cite this abstract in AMA style:

Kobayashi D, Takamura S, Wada Y, Kuroda T, Narita I. Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/risk-factors-for-cytomegalovirus-infection-in-patients-with-autoimmune-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-cytomegalovirus-infection-in-patients-with-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology